Key Investment Highlights:
- The data has illustrated that NTI164’s treatment is associated with a significant reduction in diseases severity (1.1 scale change, c. 26% global improvement)
- Approximately 40% of the subjects were markedly or severely ill at baseline, however 0% were from 4 weeks onwards
About the Phase I / II ASD Clinical Trial
- Neurotech completed the Phase I / II clinical trial to rigorously assess the safety of NTI164 in a dose-escalation regime and to form the foundation for follow-up studies. It was an open-label study, with children (n=14) aged between 8 and 17 years that have a medical diagnosis of ASD.
- After 28 days of treatment, 93% of patients showed symptom improvement relating to the severity of the illness with a statistically significant and clinically meaningful change. There were no serious adverse effects, and the drug was well tolerated across all dosage (ASX release July 2022).
- Owing to the promising safety and efficacy results, all patients requested to stay on treatment for up to 54 weeks, with Neurotech collecting additional safety and efficacy data at pre-defined periods, including at 20 weeks.
